103.18
+1.16%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About HOB Biotech Group Corp
Its shares trade on Shanghai under the ticker 688656.SS. It has been listed since 13 January 2021. In the fiscal year to 31 December 2025, it reported revenue of CN¥398.4m and net income of CN¥23.2m. At that date it held total assets of CN¥931.3m and shareholders' equity of CN¥820.0m.
HOB Biotech Group Corp. Ltd. engages in the research and development, production, and sale of in-vitro diagnostic reagents. The company is headquartered in Suzhou, Jiangsu. The company went IPO on 2021-01-13. The firm provides two categories of products: allergy testing products and self-immune testing products. Its detection techniques include qualitative detection techniques such as enzyme-linked immunosorbent assay, and quantitative detection techniques such as enzyme-linked immunoassay capture method and nano-magnetic particle chemiluminescence method. The brands of allergy testing products include Oboke, Fubok, Shibok and Shibok Plus. The self-immune testing product brands include Norbok and Nabok. The company is also engaged in the provision of reagent supporting testing instruments and others. The firm conducts its businesses in the domestic market.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 13 Jan 2021
- Employees
- 488
- Website
- hob-biotech.com ↗
Leadership
Pay as last reported
- Mr. Kai WangVice Chairman of the Board, since 2023
- Ms. Xiaohua HuangVice President - Supply Chain, Deputy General Manager
- Mr. Qingxin LiuDeputy General Manager, Director
- Mr. Ruoliang SunDeputy General Manager
- Ms. Aixiang XieSecretary of the Board
- Mr. John LiDirector
- Mr. Feng XiongDirector
- Mr. Rong HuangIndependent Director
- Mr. Yuehong QianIndependent Director
- Mr. Qiang XiaoIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- HOB Biotech's allergy testing brands Oboke and Fubok lead domestic market share in China.
- Self-immune testing brands Norbok and Nabok offer advanced quantitative detection techniques.
- 488 employees support R&D and production of in-vitro diagnostic reagents in Suzhou.
Weaknesses
- Limited domestic market focus restricts international expansion opportunities.
- No mention of international market presence or global partnerships in business description.
- IPO date 13 January 2021 indicates relatively recent market entry.
Opportunities
- Growing demand for allergy testing products in China's health care sector.
- Expansion of self-immune testing product lines with Norbok and Nabok brands.
- Increasing adoption of nano-magnetic particle chemiluminescence methods in diagnostics.
Threats
- Competition from established domestic biotechnology firms in China.
- Dependence on domestic market may limit resilience against economic downturns.
- No indication of regulatory changes affecting biotechnology sector in China.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.